Rationalisation of previous multiple insulin treatment by switching to a fixed combination of basal insulin degludec and the GLP1-receptor agonist liraglutide (IDegLira): results of the SIMPLIFY study after 14 weeks

Authors: Emil Martinka 1;  Rid Dravecká 2;  Ivan Tkáč 3
Authors‘ workplace: Národný endokrinologický a diabetologický ústav, n. o., Ľubochňa 1;  I. interná klinika LF UPJŠ a UNLP Košice 2;  Excelentný tím pre výskum aterosklerózy (EXTASY), IV. interná klinika LF UPJŠ a UN LP Košice 3
Published in: Forum Diab 2022; 11(Supplementum): 6-14


Characteristics and aim of the study: A non-randomized, open-label, multicenter, single-arm prospective study in Real Word Evidence (RWE) with aim to evaluate whether switching from basal insulin + prandial insulin boluses (IIT) to fixed-combination of the basal insulin analogue degludec and the GLP-1 receptor agonist liraglutide (IDegLira) in patients with type 2 diabetes mellitus (DM2T) is at least as effective as previous IIT treatment in terms of glycemic control, body weight, blood pressure and blood fat levels. (Analysis of results after the first 14 weeks). Materials and methods: The study enrolled 147 patients with DM2T with duration > 5 years, on IIT treatment > 12 months, with HbA1c > 7 %, with preserved insulin secretion and total daily insulin dose (TDDI) < 0.7 IU/kg body weight resp. < 70 IU/day. Parameters of glyc­emic control (HbA1c, glycemia in glycemic profiles) were compared during the treatment of IIT and subsequently after 14 weeks of treatment after switching to IDegLira. In a subgroup (n = 31) patients, continuous glucose monitoring (CGM) was performed and parameters time in range (TIR) were evaluated. Other endpoints were body weight (BW), body mass index (BMI), blood pressure, lipids, hypoglycemia, and insulin doses were evaluated. Switch from IIT to IDegLira was performed in a single ambulatory session with an initial dose of IDegLira up to 16  DU (Dose Units) followed by a titration of ± 2–4 DU / 3 days. Results: Analysis of the results after the first 14 weeks of treatment showed that the switch from IIT to IDegLira was associated with a significant improvement both with HbA1c (8.6 ± 0.9 vs 7.7 ± 1.2, p < 0,0001) and plasma glucose levels in glyc­emic profiles. TIR (time in range) and TAR (time above range) values were also improved, but the difference was not statistically significant. Change of treatment has also been associated with significant reductions in BW (97.7 ± 18.3 vs 94.2 ± 17.9, p < 0,0001), BMI, systolic blood pressure, triglycerides, total cholesterol and LDL-cholesterol. There was also significant reductions in frequency of hypoglycemia both in selfmonitoring (0.52 vs 0.03 episodes per patient, 19,7 % vs 3,4 % proportion of patients) and TBR („time below range“) 2.8 % vs 0.8 %, p < 0,05 in CGM, and a significant decrease in insulin doses (55.6 ± 14.3 vs 30.9 ± 9.4, p < 0,0001). Conclusion: Switch from IIT to IDegLira in DM2T with HbA1c > 7 %, preserved insulin secretion and TDDI < 70 IU is safe, effective and less demanding form of treatment, the benefit of which manifests already after 14 weeks of treatment.


type 2 diabetes mellitus – CGM – IDegLira – intensified insulin treatment – simplification

  1. Martinka E, Mokáň M, Tkáč I et al. Interdisciplinárne odporúčania pre diagnostiku a liečbu diabetes mellitus , jeho komplikácií a najvýznamnejšéch sprievodných ochorení – 2021. Forum Diabetologicum 2021; 10(Suppl 2).
  2. Davies MJ, D‘Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61 (12): 2461–2498. Dostupné z DOI: <http://doi: 10.1007/s00125–018–4729–5. Erratum in: Diabetologia. 2019; 62(5): 873. PMID: 30288571>.
  3. Uzunlulu M, Oguz et al. C-peptide concentrations in patients with type 2 diabetes treated with insulin. Diabetes Metab Syndr 2019; 13(6): 3099–3104. Dostupné z DOI: <http://doi: 10.1016/j.dsx.2019.11.010>.
  4. Haluzík M, Flekač M, Lengyel C et al. Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective. Diabetes Ther 2020; 11(4): 1029–1043. Dostupné z DOI: <http://doi: 10.1007/s13300–020–00777–2>.
  5. Nauck MA, Meier JJ. Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells? Nat Rev Endocrinol 2011; 7(4): 193–195. Dostupné z DOI: <http://doi: 10.1038/nrendo.2011.30>.
  6. Iorga RA, Bacalbasa N, Carsote M et al. Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Exp Ther Med 2020; 20(3): 2396–2400. Dostupné z DOI: <http://doi: 10.3892/etm.2020.8714>.
  7. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311–322. Dostupné z DOI: <http://doi: 10.1056/NEJMoa1603827>.
  8. Psota M, Psenkova MB, Racekova N et al. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. Clinicoecon Outcomes Res 2017; 9: 749–762. Dostupné z DOI: <http://doi: 10.2147/CEOR.S143127>.
  9. Watada H, Ross Agner BF, Doshi A et al. IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy. Diabetes Ther 2020; 11(1): 331–339. Dostupné z DOI: <http://doi: 10.1007/s13300–019–00730-y>.
  10. Taybani Z, Bótyik B, Katkó M et al. Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes. Diabetes Ther 2019; 10: 1869–1878. Dostupné z DOI: <http://doi.org/10.1007/s13300–019–0673–8>.
  11. Price H, Blüher M, Prager R et al. [EXTRA study group]. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study. Diabetes Obes Metab 2018; 20(4): 954–962.
  12. Persano M, Nollino L, Sambataro M et al. Real-word study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy. European Review for Medical and Pharmacological Sciences 2021; 25: 923–931.
  13. Battelino T, Danne T, Bergenstal RM et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019; 42(8):1593-1603. Dostupné z DOI: <http://doi: 10.2337/dci19-0028>.
Diabetology Endocrinology Internal medicine

Article was published in

Forum Diabetologicum

Issue Supplementum

2022 Issue Supplementum

Most read in this issue
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account